Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CJM112 in Moderate to Severe Inflammatory Acne
2016-002492-95Phase 2Terminated
- Sponsor
- Novartis
- Start
- Sep 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in acne vulgaris comparing CJM112 with Placebo (2 arms). Primary endpoint: Total inflammatory facial lesion count. Started Sep 2016; status: terminated.
02
Drugs
CJM112
03
Conditions
acne vulgaris
Beyond the preview
Go deeper on 2016-002492-95.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002492-95.